These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27006304)

  • 1. Vaccine adjuvants as potential cancer immunotherapeutics.
    Temizoz B; Kuroda E; Ishii KJ
    Int Immunol; 2016 Jul; 28(7):329-38. PubMed ID: 27006304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
    Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
    Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
    Jahrsdörfer B; Weiner GJ
    Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
    Tam YK
    J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
    Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
    Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
    Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo.
    Linghua Z; Xingshan T; Fengzhen Z
    Int Immunopharmacol; 2006 Aug; 6(8):1267-76. PubMed ID: 16782539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
    Kobiyama K; Ishii KJ
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.
    Zhang W; An M; Xi J; Liu H
    Bioconjug Chem; 2017 Jul; 28(7):1993-2000. PubMed ID: 28644608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
    Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
    Front Immunol; 2022; 13():936129. PubMed ID: 36059502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-based immunotherapeutics for the treatment of allergic disease.
    Horner AA; Van Uden JH; Zubeldia JM; Broide D; Raz E
    Immunol Rev; 2001 Feb; 179():102-18. PubMed ID: 11292014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA.
    Creticos PS; Chen YH; Schroeder JT
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):569-81, v. PubMed ID: 15474859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING-mediated DNA sensing in cancer immunotherapy.
    Zhou X; Jiang Z
    Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives.
    Francis JN; Durham SR
    Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):543-8. PubMed ID: 15640697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.